Yoon YH, et al. - Researchers examined the incidence, management, and prognostic impact of new-onset atrial fibrillation (NOAF) after transcatheter aortic valve implantation (TAVI) for severe aortic valve stenosis (AS) in 347 consecutive patients who had TAVI between March 2010 and August 2017 in the prospective ASAN-TAVI registry. Among participants, 50 patients had pre-existing AF, 31 patients had NOAF, and 266 patients had no AF, and these three groups were assessed for the primary endpoint ie, a composite of stroke or systemic embolism at 12 months. Findings revealed NOAF in 10% of patients without pre-existing AF, and stroke or systemic embolization was experienced by 1 of 4 NOAF patients. In 13 (41.9%) and 6 (19.4%) patients, pharmacologic and electrical cardioversion were tried, respectively, and respective 61.5% and 33.3% success rates were observed. A substantially higher risk of stroke or systemic embolization was observed in association with the presence of NOAF.